A sensitive and specific assay for the serological diagnosis of antilaminin 332 mucous membrane pemphigoid

S. Goletz, C. Probst, L. Komorowski, W. Schlumberger, K. Fechner, N. van Beek, M. M. Holtsche, A. Recke, Kim Yancey, T. Hashimoto, F. Antonicelli, G. Di Zenzo, D. Zillikens, W. Stöcker, E. Schmidt

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Antilaminin 332 mucous membrane pemphigoid (MMP) is an autoimmune subepidermal blistering disease with predominant mucosal involvement and autoantibodies against laminin 332. Malignancies have been associated with this disease; however, no standardized detection system for antilaminin 332 serum antibodies is widely available. Objectives: Development of a sensitive and specific assay for the detection of antilaminin 332 antibodies. Methods: An indirect immunofluorescence (IF) assay using recombinant laminin 332 was developed and probed with a large number of antilaminin 332 MMP patient sera (n = 93), as well as sera from patients with antilaminin 332-negative MMP (n = 153), bullous pemphigoid (n = 20), pemphigus vulgaris (n = 20) and noninflammatory dermatoses (n = 22), and healthy blood donors (n = 100). Results: In the novel IF assay, sensitivities with the laminin 332 heterotrimer and the individual α3, β3 and γ2 chains were 77%, 43%, 41% and 13%, respectively, with specificities of 100% for each substrate. The sensitivity for the heterotrimer increased when an anti-IgG4 enriched antitotal IgG conjugate was applied. Antilaminin 332 reactivity paralleled disease activity and was associated with malignancies in 25% of patients with antilaminin 332 MMP. Conclusions: The novel IF-based assay will facilitate the serological diagnosis of antilaminin 332 MMP and may help to identify patients at risk of a malignancy.

Original languageEnglish (US)
JournalBritish Journal of Dermatology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Bullous Pemphigoid
Mucous Membrane
Fluorescent Antibody Technique
Immunoglobulin G
Serum
Neoplasms
Pemphigus
Antibodies
Indirect Fluorescent Antibody Technique
Blood Donors
Skin Diseases
Autoantibodies
kalinin

ASJC Scopus subject areas

  • Dermatology

Cite this

Goletz, S., Probst, C., Komorowski, L., Schlumberger, W., Fechner, K., van Beek, N., ... Schmidt, E. (Accepted/In press). A sensitive and specific assay for the serological diagnosis of antilaminin 332 mucous membrane pemphigoid. British Journal of Dermatology. https://doi.org/10.1111/bjd.17202

A sensitive and specific assay for the serological diagnosis of antilaminin 332 mucous membrane pemphigoid. / Goletz, S.; Probst, C.; Komorowski, L.; Schlumberger, W.; Fechner, K.; van Beek, N.; Holtsche, M. M.; Recke, A.; Yancey, Kim; Hashimoto, T.; Antonicelli, F.; Di Zenzo, G.; Zillikens, D.; Stöcker, W.; Schmidt, E.

In: British Journal of Dermatology, 01.01.2018.

Research output: Contribution to journalArticle

Goletz, S, Probst, C, Komorowski, L, Schlumberger, W, Fechner, K, van Beek, N, Holtsche, MM, Recke, A, Yancey, K, Hashimoto, T, Antonicelli, F, Di Zenzo, G, Zillikens, D, Stöcker, W & Schmidt, E 2018, 'A sensitive and specific assay for the serological diagnosis of antilaminin 332 mucous membrane pemphigoid', British Journal of Dermatology. https://doi.org/10.1111/bjd.17202
Goletz, S. ; Probst, C. ; Komorowski, L. ; Schlumberger, W. ; Fechner, K. ; van Beek, N. ; Holtsche, M. M. ; Recke, A. ; Yancey, Kim ; Hashimoto, T. ; Antonicelli, F. ; Di Zenzo, G. ; Zillikens, D. ; Stöcker, W. ; Schmidt, E. / A sensitive and specific assay for the serological diagnosis of antilaminin 332 mucous membrane pemphigoid. In: British Journal of Dermatology. 2018.
@article{38340c3a82954a93b9979c88f8dccbfb,
title = "A sensitive and specific assay for the serological diagnosis of antilaminin 332 mucous membrane pemphigoid",
abstract = "Background: Antilaminin 332 mucous membrane pemphigoid (MMP) is an autoimmune subepidermal blistering disease with predominant mucosal involvement and autoantibodies against laminin 332. Malignancies have been associated with this disease; however, no standardized detection system for antilaminin 332 serum antibodies is widely available. Objectives: Development of a sensitive and specific assay for the detection of antilaminin 332 antibodies. Methods: An indirect immunofluorescence (IF) assay using recombinant laminin 332 was developed and probed with a large number of antilaminin 332 MMP patient sera (n = 93), as well as sera from patients with antilaminin 332-negative MMP (n = 153), bullous pemphigoid (n = 20), pemphigus vulgaris (n = 20) and noninflammatory dermatoses (n = 22), and healthy blood donors (n = 100). Results: In the novel IF assay, sensitivities with the laminin 332 heterotrimer and the individual α3, β3 and γ2 chains were 77{\%}, 43{\%}, 41{\%} and 13{\%}, respectively, with specificities of 100{\%} for each substrate. The sensitivity for the heterotrimer increased when an anti-IgG4 enriched antitotal IgG conjugate was applied. Antilaminin 332 reactivity paralleled disease activity and was associated with malignancies in 25{\%} of patients with antilaminin 332 MMP. Conclusions: The novel IF-based assay will facilitate the serological diagnosis of antilaminin 332 MMP and may help to identify patients at risk of a malignancy.",
author = "S. Goletz and C. Probst and L. Komorowski and W. Schlumberger and K. Fechner and {van Beek}, N. and Holtsche, {M. M.} and A. Recke and Kim Yancey and T. Hashimoto and F. Antonicelli and {Di Zenzo}, G. and D. Zillikens and W. St{\"o}cker and E. Schmidt",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/bjd.17202",
language = "English (US)",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - A sensitive and specific assay for the serological diagnosis of antilaminin 332 mucous membrane pemphigoid

AU - Goletz, S.

AU - Probst, C.

AU - Komorowski, L.

AU - Schlumberger, W.

AU - Fechner, K.

AU - van Beek, N.

AU - Holtsche, M. M.

AU - Recke, A.

AU - Yancey, Kim

AU - Hashimoto, T.

AU - Antonicelli, F.

AU - Di Zenzo, G.

AU - Zillikens, D.

AU - Stöcker, W.

AU - Schmidt, E.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Antilaminin 332 mucous membrane pemphigoid (MMP) is an autoimmune subepidermal blistering disease with predominant mucosal involvement and autoantibodies against laminin 332. Malignancies have been associated with this disease; however, no standardized detection system for antilaminin 332 serum antibodies is widely available. Objectives: Development of a sensitive and specific assay for the detection of antilaminin 332 antibodies. Methods: An indirect immunofluorescence (IF) assay using recombinant laminin 332 was developed and probed with a large number of antilaminin 332 MMP patient sera (n = 93), as well as sera from patients with antilaminin 332-negative MMP (n = 153), bullous pemphigoid (n = 20), pemphigus vulgaris (n = 20) and noninflammatory dermatoses (n = 22), and healthy blood donors (n = 100). Results: In the novel IF assay, sensitivities with the laminin 332 heterotrimer and the individual α3, β3 and γ2 chains were 77%, 43%, 41% and 13%, respectively, with specificities of 100% for each substrate. The sensitivity for the heterotrimer increased when an anti-IgG4 enriched antitotal IgG conjugate was applied. Antilaminin 332 reactivity paralleled disease activity and was associated with malignancies in 25% of patients with antilaminin 332 MMP. Conclusions: The novel IF-based assay will facilitate the serological diagnosis of antilaminin 332 MMP and may help to identify patients at risk of a malignancy.

AB - Background: Antilaminin 332 mucous membrane pemphigoid (MMP) is an autoimmune subepidermal blistering disease with predominant mucosal involvement and autoantibodies against laminin 332. Malignancies have been associated with this disease; however, no standardized detection system for antilaminin 332 serum antibodies is widely available. Objectives: Development of a sensitive and specific assay for the detection of antilaminin 332 antibodies. Methods: An indirect immunofluorescence (IF) assay using recombinant laminin 332 was developed and probed with a large number of antilaminin 332 MMP patient sera (n = 93), as well as sera from patients with antilaminin 332-negative MMP (n = 153), bullous pemphigoid (n = 20), pemphigus vulgaris (n = 20) and noninflammatory dermatoses (n = 22), and healthy blood donors (n = 100). Results: In the novel IF assay, sensitivities with the laminin 332 heterotrimer and the individual α3, β3 and γ2 chains were 77%, 43%, 41% and 13%, respectively, with specificities of 100% for each substrate. The sensitivity for the heterotrimer increased when an anti-IgG4 enriched antitotal IgG conjugate was applied. Antilaminin 332 reactivity paralleled disease activity and was associated with malignancies in 25% of patients with antilaminin 332 MMP. Conclusions: The novel IF-based assay will facilitate the serological diagnosis of antilaminin 332 MMP and may help to identify patients at risk of a malignancy.

UR - http://www.scopus.com/inward/record.url?scp=85056104898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056104898&partnerID=8YFLogxK

U2 - 10.1111/bjd.17202

DO - 10.1111/bjd.17202

M3 - Article

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

ER -